Market Overview

Morgan Stanley Modestly Adjusts Share Assumptions For Edwards Lifesciences

Share:
Related EW
Goldman Remains Constructive on MedTech, Sees 'New Opportunities' Amid Selloff
Goldman's New Pair Trade Opportunity

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Edwards Lifesciences (NYSE: EW).

In the report, Morgan Stanley noted, “Our Edwards numbers are going modestly higher as the positive impact of TAVR royalties is partially offset by lower assumed market share. We have reduced our US share expectations by about 200-300 bps to reflect stronger assumed competition from Medtronic, while our EU share estimates have increased slightly. In addition, we have added the Medtronic TAVR royalty to our model. We assume that Edwards receives the minimum payment of $40 million annually beginning in 3Q14. In all, our EPS estimates have increased to $3.10 in 2014 from $3.05 previously, and to $3.77 from $3.67 in 2015. In 2015, this puts us modestly above the Street in revenue and $0.10 higher than consensus for EPS.”

Edwards Lifesciences closed on Friday at $85.00.

Latest Ratings for EW

DateFirmActionFromTo
Aug 2015Credit SuisseAssumesOutperform
Jul 2015Stifel NicolausMaintainsBuy
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!

Get Benzinga's Newsletters